Skip to main content

Published locations for Sustained Remissions After Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Sustained Remissions After Discontinuation of Ibrutinib in Relapsed/Refractory CLL: A Basis for Reducing Drug Toxicity and Treatment Costs?

User login

  • Reset your password
  • /content/sustained-remissions-after-discontinuation-ibrutinib-relapsed/refractory-cll-basis-reducing
  • /fedprac/article/113158/oncology/sustained-remissions-after-discontinuation-ibrutinib-relapsed
  • /fedprac/avaho/article/113158/oncology/sustained-remissions-after-discontinuation-ibrutinib-relapsed